This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Magenta Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	2.8yrs
Board average tenure	5.8yrs

Recent management updates

Recent updates

Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?

Dec 10

Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate

Aug 25

Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?

Jul 13

Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation

Apr 12

Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation

Dec 16

Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans

Aug 26

What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

Mar 17

Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans

Jan 23

Magenta Therapeutics announces expected 2021 highlights milestones

Jan 11

What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

Dec 01

CEO

Magenta Therapeutics has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Stephen Mahoney	President	2.8yrs	US$1.12m	0.029% $ 12.1k
Shan Wu	Head of Investor Relations	no data	no data	no data
Thomas Beetham	Chief Legal Officer & Secretary	2.3yrs	US$2.09m	0.033% $ 13.9k
Catherine Monaghan	Head of Clinical Development Operations	5.5yrs	no data	no data
Jim Haney	Senior Director of Investor Relations	no data	no data	no data

2.8yrs

Average Tenure

Experienced Management: MGTA's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Thomas Daniel	Independent Director	6.9yrs	US$70.66k	0.17% $ 71.3k
Alison Lawton	Independent Chairman	2.8yrs	US$94.66k	0% $ 0
Bruce Blazar	Member of Scientific Advisory Board	4.3yrs	no data	no data
Bruce Booth	Independent Director	7.6yrs	US$59.41k	6.28% $ 2.7m
Anne McGeorge	Independent Director	4.3yrs	US$67.56k	0% $ 0
John DiPersio	Member of Scientific Advisory Board	no data	no data	no data
Amy Ronneberg	Independent Director	5.5yrs	US$58.57k	0% $ 0
Jeffrey Albers	Independent Director	6.2yrs	US$64.41k	0.0069% $ 2.9k
Luigi Naldini	Member of Scientific Advisory Board	no data	no data	no data
David Scadden	Chair of Scientific Advisory Board & Director	6.8yrs	US$119.41k	0.38% $ 159.6k
Alan Tyndall	Member of Scientific Advisory Board	no data	no data	no data
Megan Sykes	Member of Scientific Advisory Board	no data	no data	no data

5.8yrs

Average Tenure

62yo

Average Age

Experienced Board: MGTA's board of directors are considered experienced (5.8 years average tenure).

This company is no longer active

Magenta Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer

Insufficient new directors

Magenta Therapeutics, Inc. Announces the Resignation of Jason Gardner, Chief Executive Officer

Magenta Therapeutics Announces Appointment of Michael Vasconcelles to its Board of Directors, R&D Committee and Nominating and Corporate Governance Committee

Insufficient new directors

Insufficient new directors

Recent updates

Dianthus Therapeutics, Inc. completed the acquisition of Magenta Therapeutics, Inc. (NasdaqGM:MGTA) from a group of shareholders in a reverse merger transaction.

Magenta Therapeutics, Inc. Announces Resignation of Lisa Olson as Head of Research and Chief Scientific Officer

Dianthus Therapeutics, Inc. entered into a definitive merger agreement to acquire Magenta Therapeutics, Inc. (NasdaqGM:MGTA) in a reverse merger transaction.

Forecast to breakeven in 2024

Insufficient new directors

Magenta Therapeutics, Inc. Announces the Resignation of Jason Gardner, Chief Executive Officer

Magenta Therapeutics Receives a Written Notice from the Staff of the Listing Qualifications Department of the Nasdaq Stock Market

Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety

Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial

Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?

Price target decreased to US$5.00

Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate

Magenta Therapeutics Announces Appointment of Michael Vasconcelles to its Board of Directors, R&D Committee and Nominating and Corporate Governance Committee

Insufficient new directors

Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?

Insufficient new directors

Magenta Therapeutics, Inc.(NasdaqGM:MGTA) dropped from Russell 2000 Growth Index

Magenta Therapeutics, Inc., Annual General Meeting, Jun 28, 2022

Price target decreased to US$6.67

Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway

Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation

Price target decreased to US$11.83

Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022

Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation

Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning At the 2021 American Society of Hematology Annual Meeting

Co-Founder recently sold US$97k worth of stock

Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans

Price target decreased to US$15.71

Independent Chairman Michael Bonney has left the company

Price target decreased to US$17.14

Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome

Price target increased to US$19.00

Magenta Therapeutics (MGTA) EHA Investor Presentations - Slideshow

Independent Director Blake Byers has left the company

Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clinical Oncology (ASCO) Annual Meeting

Magenta Therapeutics, Inc. announced that it expects to receive $86.399982 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, Great Point Partners, LLC, OrbiMed Advisors LLC, Janus Henderson Group plc

Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117

We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate

Magenta Therapeutics EPS beats by $0.04

Chief Legal Officer & Corporate Secretary has left the company

What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marrow Transplantation (EBMT) 2021 Annual Meeting

New 90-day high: US$11.16

New 90-day high: US$9.15

Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans

Magenta Therapeutics announces expected 2021 highlights milestones

New 90-day high: US$8.67

Magenta Therapeutics, Inc. Appoints Alison F. Lawton as Director

New 90-day high: US$7.88

Magenta Therapeutics and Bluebird Bio Announce A Phase 2 Clinical Trial Collaboration to Evaluate Magenta’s MGTA-145 for Mobilizing and Collecting Stem Cells in Adults and Adolescents with Sickle Cell Disease

What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?

Magenta Therapeutics Appoints Steve Mahoney as Chief Operating Officer

Magenta Therapeutics, Inc. Appoints Steve Mahoney as Operating Officer

Magenta Therapeutics, Inc. Announces Multiple Presentations Across Stem Cell Transplant Portfolio

New 90-day low: US$6.31

Price target lowered to US$16.67

Magenta Therapeutics, Inc. Announces Executive Changes

New 90-day low - US$6.84

New 90-day low - US$7.22

CEO

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age